Quantcast

Latest Treatment of schizophrenia Stories

2010-05-21 07:00:00

TITUSVILLE, N.J., May 21 /PRNewswire/ -- New data on INVEGA® SUSTENNA® (paliperidone palmitate), a long-acting injectable medicine for schizophrenia, and new data on RISPERDAL® CONSTA® (risperidone long-acting therapy), also an injectable medicine to treat schizophrenia, will be presented next week at a major psychiatry meeting in New Orleans. Posters on this data will be presented on Wednesday, May 26, from 12 noon to...

2010-04-12 07:00:00

WALTHAM, Mass., April 12 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that Janssen's Invega Sustenna earns Decision Resources' proprietary clinical gold standard status for the treatment of schizophrenia in 2013. Invega Sustenna has competitive advantages in safety, tolerability and delivery over current and emerging therapies. "Invega Sustenna, which launched in the second half of 2009, was the...

2010-03-02 08:24:13

Gene network-based analysis reveals unexpected results The underlying causes of the debilitating psychiatric disorder schizophrenia remain poorly understood. In a new study published online in Genome Research March 2, 2010, however, scientists report that a powerful gene network analysis has revealed surprising new insights into how gene regulation and age play a role in schizophrenia. Researchers are actively working to identify the direct cause of schizophrenia, likely rooted in...

2010-02-23 08:00:00

WALTHAM, Mass., Feb. 23 /PRNewswire/ -- Decision Resources, one of the world's leading research and advisory firms for pharmaceutical and healthcare issues, finds that, in the world's major pharmaceutical markets, emerging oral atypical antipsychotics will compete against each other and against established drugs for the same niche patient population in the treatment of schizophrenia. The Pharmacor 2010 findings from the topic entitled Schizophrenia reveals that emerging oral atypical...

2010-01-11 00:30:00

Schizophrenia is a Chronic, Severe and Disabling Mental Disorder Affecting 2.4 million Americans Novartis announced that Fanapt(TM) (iloperidone), the company's schizophrenia treatment, is now available for use across the US. Fanapt is a twice-daily, oral antipsychotic, approved by the US Food and Drug Administration (FDA) in May 2009 for the acute treatment of schizophrenia in adults. Schizophrenia is a chronic, severe and disabling mental disorder, affecting 2.4 million...

2010-01-05 11:07:00

WATERTOWN, Mass., Jan. 5 /PRNewswire/ -- EnVivo Pharmaceuticals today announced the initiation and dosing of patients in a Phase 2b study of its EVP-6124 compound, a selective alpha-7 nicotinic agonist in patients with schizophrenia. EnVivo is conducting the multi-center, dose ranging, placebo controlled, three-month study in the U.S. and Europe. The study is designed to determine the safety and efficacy of EVP-6124 in producing procognitive effects and improving executive function in...

2010-01-04 17:00:00

FORT LEE, N.J., Jan. 4 /PRNewswire/ -- Dainippon Sumitomo Pharma America, Inc. (DSPA), a U.S. subsidiary of Dainippon Sumitomo Pharma Co., Ltd. (DSP), submitted a New Drug Application (NDA) to the U.S. Food and Drug Administration (FDA) for lurasidone, an investigational atypical antipsychotic agent for the treatment of schizophrenia. The application, submitted on December 30, 2009, includes data from more than 40 clinical studies involving more than 2,500 lurasidone-treated patients....

2009-12-14 07:30:00

INDIANAPOLIS, Dec. 14 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) approved ZYPREXA RELPREVV (olanzapine) For Extended Release Injectable Suspension for the treatment of schizophrenia in adults, Eli Lilly and Company (NYSE: LLY) announced today. ZYPREXA RELPREVV, a long-acting intramuscular injection, sustains the delivery of olanzapine for up to four weeks. Different from both oral and injected short-acting formulations, long-acting formulations of antipsychotics...

2009-12-10 06:57:00

TITUSVILLE, N.J., Dec. 10 /PRNewswire/ -- Treatment with once-monthly INVEGA® SUSTENNA(TM) is not inferior to treatment with bi-weekly RISPERDAL® CONSTA®, according to new data from a comparative study of both treatments in patients with schizophrenia. Results of the 13-week clinical trial were released this week. An estimated one percent of the world's population suffers from schizophrenia - a brain disorder that impairs a person's...

2009-12-04 15:30:00

INDIANAPOLIS, Dec. 4 /PRNewswire-FirstCall/ -- The U.S. Food and Drug Administration (FDA) today approved Zyprexa® (olanzapine) in tablet form as an option for the treatment of schizophrenia and manic or mixed episodes associated with bipolar I disorder in adolescents aged 13-17 years old. The updated Zyprexa label states that clinicians should take into consideration the increased potential for weight gain and hyperlipidemia in adolescents compared to adults and the...


Word of the Day
tessitura
  • The prevailing range of a vocal or instrumental part, within which most of the tones lie.
This word is Italian in origin and comes from the Latin 'textura,' web, structure.